Shire Settles Patent Row With Sandoz Over Generic Intuniv

Law360, New York (April 19, 2013, 9:26 PM EDT) -- Pharmaceuticals manufacturer Shire PLC has settled its patent infringement claims against Sandoz Inc. over the company’s attempt to develop a generic form of Intuniv, an attention deficit hyperactivity disorder drug, according to an order issued Thursday by a Colorado federal judge.

Dublin-based Shire, which slapped its rival with a pair of infringement suits in 2011 and 2012, reached a deal with the generic-drug maker under which Sandoz agreed to license the three patents-in-suit and to abstain from challenging their validity.

U.S. District Judge R. Brooke Jackson also imposed a...
To view the full article, register now.